Pham Quang X 4

What Happened
Pham Quang (listed as a 10% owner) sold a total of 8,285 shares of Cadrenal Therapeutics (CVKD) in three open-market transactions between June 3–5, 2026. The trades reported: 2,323 shares on 2026-06-03 at a weighted avg price of $4.26 (≈ $9,896); 3,898 shares on 2026-06-04 at a weighted avg price of $4.41 (≈ $17,190); and 2,064 shares on 2026-06-05 at a weighted avg price of $4.42 (≈ $9,123). Total proceeds across the three days were roughly $36,209. These were sales (not purchases), often considered routine dispositions.

Key Details

• Transaction dates and reported weighted-average prices:
  • 2026-06-03: 2,323 sh @ $4.26 (weighted avg; underlying trades ranged $4.18–$4.39)
  • 2026-06-04: 3,898 sh @ $4.41 (weighted avg; underlying trades ranged $4.19–$4.47)
  • 2026-06-05: 2,064 sh @ $4.42 (weighted avg; underlying trades ranged $4.25–$4.50)
• Total shares sold: 8,285; total proceeds ≈ $36,209.
• Shares owned after the transactions: not specified in the provided summary — see the full Form 4 for post-transaction holdings.
• Notable footnotes:
  • Sales were made under a Rule 10b5-1 trading plan adopted Sept 25, 2025 (F1).
  • Weighted-average prices and intra-day price ranges are disclosed (F2–F4); issuer or SEC staff can request detailed breakouts.
  • F5 notes Pham is trustee of The PVBQ Living Trust and has sole voting/dispositive power over trust shares.
• Filing timeliness: Form filed on 2026-06-05 covering trades through 2026-06-05 — appears to have been filed within the usual Form 4 reporting window.

Context
These transactions are sales by a 10% beneficial owner and were executed under a prearranged 10b5‑1 plan, which typically documents timing and amounts in advance. Sales by large holders can reflect portfolio management rather than a view on company prospects; they are not the same signal as an executive purchase. For full ownership details and exact per-trade prices, consult the complete SEC Form 4 (Accession: 0001213900-26-065925).